Inovio Pharmaceuticals Gains Favorable Analyst Rating with $5 Price Target

Inovio Pharmaceuticals Inc. (INO) has been assigned an Overweight rating with a $5 price target by Piper Sandler analyst Edward Tenthoff. The company is developing DNA-encoded medicines for various conditions, including cancer, infectious diseases, and rare diseases. INO-3107, a treatment for recurrent respiratory papillomatosis, has shown promising results in Phase I/II trials. The average one-year price target for INO is $8.00, with an upside of 497.01% from the current price of $1.34. The estimated GF Value for INO in one year is $1.64, suggesting a 22.39% upside.

Inovio Pharmaceuticals Inc. (INO) has received an Overweight rating with a $5 price target from Piper Sandler analyst Edward Tenthoff, as reported by TipRanks [1]. The company, which specializes in developing DNA-encoded medicines for various conditions including cancer, infectious diseases, and rare diseases, has shown promising results in its Phase I/II trials for INO-3107, a treatment for recurrent respiratory papillomatosis.

The recent Phase I/II trial data, published in the medical journal Nature Communications, demonstrated that INO-3107 was well-tolerated and achieved robust clinical efficacy, with 81% of patients requiring fewer surgeries and 28% experiencing no surgeries at all [2]. These results have contributed to the bullish view expressed by Tenthoff, who cited the potential for FDA approval of INO-3107 next year.

Inovio Pharmaceuticals' stock has gained significant attention from analysts, with an average one-year price target of $8.00, representing an upside of 497.01% from the current price of $1.34. The estimated GF Value for INO in one year is $1.64, suggesting a 22.39% upside.

Analysts have been generally optimistic about Inovio's prospects, with a consensus rating of Moderate Buy based on 3 buy ratings, 3 hold ratings, and 0 sell ratings. The average 12-month price target is $6.67, with a high forecast of $13.00 and a low forecast of $2.00. The average price target represents a 360.00% increase from the current price of $1.45 [1].

While the company faces significant financial and technical challenges, reflected in its low financial performance and valuation scores, there is progress in regulatory submissions and cost management. The ongoing financial difficulties and bearish technical indicators continue to impact the overall score, but the potential for FDA approval of INO-3107 offers a glimmer of hope for investors.

References:
[1] TipRanks. (n.d.). Inovio Pharmaceuticals Inc. (INO) Analyst Ratings. Retrieved from [https://www.tipranks.com/stocks/ino/forecast](https://www.tipranks.com/stocks/ino/forecast)
[2] George Clerk. (n.d.). Inovio Stock on Piper Sandler: Bullish View. Retrieved from [https://seekingalpha.com/news/4466229-inovio-stock-on-piper-sandler-bullish-view](https://seekingalpha.com/news/4466229-inovio-stock-on-piper-sandler-bullish-view)